Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Core Insights - Calidi Biotherapeutics has appointed Eric Poma, Ph.D., as the new CEO, succeeding Allan Camaisa, effective April 22, 2025 [1][2][3] - The company is advancing its systemic enveloped virotherapy platform and preparing for a dose escalation trial of CLD-201 in adult patients with solid tumors [2][3] - Dr. Poma brings over 30 years of experience in the biopharmaceutical industry, with a strong background in capital fundraising and clinical program development [2][3] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using proprietary technology [4] - The company utilizes allogeneic stem cells to deliver oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [4] - Calidi's platforms aim to enhance the efficacy and safety of oncolytic viruses, potentially treating or preventing metastatic disease [4]